| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NCPRHEUM0789 |
| P698 | PubMed publication ID | 18349862 |
| P2093 | author name string | Christy Sandborg | |
| Stacy P Ardoin | |||
| Laura Schanberg | |||
| P2860 | cites work | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| Aspirin for the primary prevention of cardiovascular events: recommendation and rationale | Q28192095 | ||
| Statin therapy and autoimmune disease: from protein prenylation to immunomodulation | Q28236647 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
| Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey | Q31919181 | ||
| Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage | Q33341018 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 | ||
| Compendium of physical activities: classification of energy costs of human physical activities | Q34348533 | ||
| Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus | Q35552185 | ||
| Clinical interest of PPARs ligands | Q35695439 | ||
| Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk | Q35876331 | ||
| Protein, body weight, and cardiovascular health | Q36186066 | ||
| Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid | Q36384542 | ||
| Statins in the treatment of central nervous system autoimmune disease | Q36543684 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus | Q36806527 | ||
| Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force | Q36868062 | ||
| Making the diagnosis of systemic lupus erythematosus in children and adolescents | Q36915623 | ||
| Management of dyslipidemia in children and adolescents with systemic lupus erythematosus | Q36915663 | ||
| Mortality in systemic lupus erythematosus | Q38467155 | ||
| Secondary causes of hyperlipidemia. | Q40802331 | ||
| Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 | ||
| The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus. | Q41946752 | ||
| The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 | ||
| Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study | Q43809261 | ||
| Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study | Q44383942 | ||
| Statin treatment in children with familial hypercholesterolemia: the younger, the better | Q44416450 | ||
| Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study | Q44652580 | ||
| Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus | Q44929993 | ||
| Cardiac risk factor awareness and management in patients with systemic lupus erythematosus | Q45184356 | ||
| Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome | Q46262236 | ||
| Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome | Q46367698 | ||
| Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria | Q46903227 | ||
| Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus | Q46973423 | ||
| Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction | Q47273525 | ||
| Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. | Q50851718 | ||
| Garlic extract therapy in children with hypercholesterolemia. | Q51566940 | ||
| Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. | Q54340050 | ||
| Prevention Conference V : Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Noninvasive Tests of Atherosclerotic Burden : Writing Group III | Q56567994 | ||
| Risk factors for coronary artery disease in patients with systemic lupus erythematosus | Q67586359 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus | Q73904664 | ||
| Diet, lipoproteins, and coronary heart disease | Q77452772 | ||
| Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006 | Q80312735 | ||
| Patient education on cardiovascular aspects of rheumatoid disease: an unmet need | Q80833783 | ||
| ??? | Q28275865 | ||
| P433 | issue | 5 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 258-265 | |
| P577 | publication date | 2008-03-18 | |
| P1433 | published in | Nature Clinical Practice Rheumatology | Q15752269 |
| P1476 | title | Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus | |
| P478 | volume | 4 |
| Q51196776 | Children and adolescents with SLE: not just little adults. |
| Q42930967 | Efficacy of ginsenosides combined with prednisone in patients with systemic lupus erythematosus: a prospective, randomized, double-blind, placebo-controlled trial |
| Q33602858 | Metabolic abnormalities and cardiovascular risk factors in children with myositis |
| Q37777642 | Prevalence and burden of pediatric-onset systemic lupus erythematosus |
| Q35835877 | Statin therapy in lupus-mediated atherogenesis: two birds with one stone? |
| Q33818710 | Use of atorvastatin in systemic lupus erythematosus in children and adolescents |
Search more.